Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030

Structure Therapeutics (GPCR) maintains a Buy rating, driven by strong Phase 2b data for its oral GLP-1 candidate aleniglipron targeting obesity. Aleniglipron demonstrated up to 16.2% weight loss at 44 weeks, a favorable discontinuation rate, and is now in Phase 3 studies with pivotal data expected Q4 2028. GPCR’s $1.34bn cash position is expected to fund completion of Phase 3, supporting a runway through key value inflection points despite high R&D burn. Market risks include increasing oral GLP-1 competition and potential Phase 3 failure, but efficacy and cost advantages position GPCR for blockbuster potential.